This proposal will create a center for Large Scale Production of Perturbagen-lnduced Cellular Signatures at Harvard Medical School and collaborating institutions, with a focus on perturbations provoked by small molecule drugs and cellular signatures measured using diverse biochemical and single-cell assays. The result will be a large, self-consistent and diverse set of network-centric Pharmacological Response Signatures that provide unique insight into disease processes, drug mechanism/selectivity and ultimately patient-specific responses to therapy. The initial focus of the Center will be small molecule kinase inhibitors, versatile perturbagens with high translational potential. We will use known inhibitors and also expand dramatically the publicly documented collection of inhibitors through new medicinal chemistry and use of kinome-wide selectivity assays. The responses of a large collection of human tumor cells and some primary cells to kinase inhibitors, will be assayed using multiplex biochemical assays (for 20-100 proteins) involving bead-based sandwich immunoassays and reverse-phase lysate microarrays, and single-cell assays (using imaging and flow cytometry) for cell cycle state, commitment to senescence or apoptosis, mesenchymal vs. epithelial phenotype and markers of primitive (stem-cell) status. Data will be collected, integrated and distributed using a series of novel, interoperable software tools that manipulate semantically-typed data arrays based on a new XML/HDF5 format. A multi-faceted informatics program will link these phenotypic and biochemical measures of cellular response to a rich and growing set of genomic data being collected by others. These goals will be met through pursuit of six linked specific aims.
Aim 1 will focus on existing - largely clinical grade - kinase inhibitors and a set of 45 cell lines that are known to display diverse drug responses and for which extensive genomic data are available.
Aim 2 will enlarge the set of perturbagens by developing a large library of kinase inhibitors using new and existing chemistry and profiling biochemical specificity across the kinome.
Aim 3 will combine existing and novel compounds in a dose-response analysis across a set of >1000 tumor cell lines to identify representative cell lines and outliers which, in Aim 4, will subjected to detailed analysis at a single-cell level.
Aims 5 -6 will develop and deploy the information processing systems needed to collect, systematize and distribute diverse data types. This will involve a novel set of interoperable software tools that incorporate emerging no-SQL and semantic web concepts. Methods for adaptive experimental design will be developed to focus data collection on those areas of the dose response landscape where signatures are most informative. The final product will be a large publicly available data set radically different from, but highly complementary to, the expression profiles and genome data that are the primary focus of current high-throughput biological studies on perturbagen-induced cellular signatures.
Plans for an HMS-based LINCS Center are directly relevant to programmatic goals of assembling mechanism-based associations among the effects of disparate biological perturbations and insight into the mechanisms of action of known drugs. Single -cell and biochemical data generated by the HMS LINCS Center will be different from and complementary to existing large scale data based on genomic assays and transcriptional profiles. The Center's focus on clinical-grade and novel kinase inhibitors will provide data with high translational potential for a class of compounds that currently dominates investigational new drugs for cancer.
|Barrette, Anne Marie; Bouhaddou, Mehdi; Birtwistle, Marc R (2018) Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chem Neurosci 9:118-129|
|Graim, Kiley; Liu, Tiffany Ting; Achrol, Achal S et al. (2017) Revealing cancer subtypes with higher-order correlations applied to imaging and omics data. BMC Med Genomics 10:20|
|Liu, Tiffany T; Achrol, Achal S; Mitchell, Lex A et al. (2017) Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro Oncol 19:997-1007|
|Lapek Jr, John D; Greninger, Patricia; Morris, Robert et al. (2017) Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities. Nat Biotechnol 35:983-989|
|Newton, Yulia; Novak, Adam M; Swatloski, Teresa et al. (2017) TumorMap: Exploring the Molecular Similarities of Cancer Samples in an Interactive Portal. Cancer Res 77:e111-e114|
|Farshidfar, Farshad; Zheng, Siyuan; Gingras, Marie-Claude et al. (2017) Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 18:2780-2794|
|Sokolov, Artem; Carlin, Daniel E; Paull, Evan O et al. (2016) Pathway-Based Genomics Prediction using Generalized Elastic Net. PLoS Comput Biol 12:e1004790|
|Si, H; Lu, H; Yang, X et al. (2016) TNF-? modulates genome-wide redistribution of ?Np63?/TAp73 and NF-?B cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer. Oncogene 35:5781-5794|
|Liu, T T; Achrol, A S; Mitchell, L A et al. (2016) Computational Identification of Tumor Anatomic Location Associated with Survival in 2 Large Cohorts of Human Primary Glioblastomas. AJNR Am J Neuroradiol 37:621-8|
|Adler, Melanie; Ramm, Susanne; Hafner, Marc et al. (2016) A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol 27:1015-28|
Showing the most recent 10 out of 74 publications